Aspects on human amyloid forms and their fibril polypeptides

FEBS Journal

Volumn 272, Issue 23, 2005, Pages 5942-5949

  Westermark, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Amyloid; Deposition; Prion; Protein folding; Seeding

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; POLYPEPTIDE;

ALZHEIMER DISEASE; AMYLOIDOSIS; DISEASE TRANSMISSION; ESCHERICHIA COLI; HUMAN; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SHORT SURVEY;

AMYLOID; AMYLOIDOSIS; ANIMALS; HUMANS; PEPTIDES; TISSUE DISTRIBUTION;

ESCHERICHIA COLI;

EID: 28244446220     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.05024.x     Document Type: Short Survey

References (55)

1. Virchow R (1854) Ueber eine im Gehirn und Ruckenmark des Menschen aufgefunde Substanz mit der chemishen Reaction der Cellulose. Virchows Arch Pathol Anat 6, 135-138.
2. Cavanagh JB (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res Rev 29, 265-295.
3. Eanes ED & Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16, 673-677.
4. Glenner GG (1980) Amyloid deposits and amyloidosis. The β-fibrilloses. N Engl J Med 302, 1283-1292; 1333-1343.
5. Jin L-W et al. (2003) Imaging linear birefringence and dichroism in cerebral amyloid pathologies. Proc Natl Acad Sci USA 100, 15294-15298.
6. Shirahama T & Cohen AS (1967) High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol 33, 679-708.
7. Perutz MF, Finch JT, Berriman J & Lesk A (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci USA 99, 5591-5595.
8. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ & Sipe JD (2005) Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12, 1-4.
9. Bitan G, Fradinger EA, Spring SM & Teplow DB (2005) Neurotoxic protein oligomers - what you see is not always what you get. Amyloid 12, 88-95.
10. Waldenström JG (1978) Necessary diagnostic pigeon-holes - defence of taxonomy in medicine as well as in botany. Acta Med Scand 203, 145-147.
11. Buxbaum JN (2003) Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? Trends Biochem Sci 28, 585-592.
12. Wisniewski T, Golabek AA, Kida E, Wisniewski KE & Frangione B (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 147, 238-244.
13. Connors LH, Lim A, Prokaeva T, Roskens VA & Costello CE (2003) Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10, 160-184.
14. Stevens FJ & Kisilevsky R (2000) Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 57, 441-449.
15. Bossy-Wetzel E, Schwarzenbacher R & Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10, S2-S9.
16. Caughey B & Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267-298.
17. Janson J, Ashley RH, Harrison D, McIntyre S & Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
18. Westermark P, Li Z-C, Westermark GT, Leckström A & Steiner DF (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379, 203-206.
19. Waugh DF (1946) A fibrous modification of insulin. I. The heat precipitate of insulin. J Am Chem Soc 68, 247-250.
20. Kisilevsky R (2000) Amyloidogenesis - unquestioned answers and unanswered questions. J Struct Biol 130, 99-108.
21. Li JP et al. (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 102, 6473-6477.
22. Olsen KE, Sletten K & Westermark P (1998) Fragments of the constant region of immunoglobulin light chain are constituents of AL-amyloid proteins. Biochem Biophys Res Commun 251, 642-647.
23. Engvig JP, Olsen KE, Gislefoss RE, Sletten K, Wahlström O & Westermark P (1998) Constant region of a κ III immunoglobulin light chain as a major AL-amyloid protein. Scand J Immunol 48, 92-98.
24. Wally J, Kica G, Zhang Y, Ericsson T, Connors LH, Benson MD, Liepnieks JJ, Murray J, Skinner M & Comenzo RL (1999) Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa 1 light chain. Biochim Biophys Acta 1454, 49-56.
25. Wall J, Murphy CL & Solomon A (1999) In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol 309, 204-217.
26. Ein D, Kimura S, Terry WD, Magnotta J & Glenner GG (1972) Amino acid sequence of an amyloid fibril protein of unknown origin. J Biol Chem 247, 5653-5655.
27. Westermark GT, Sletten K, Grubb A & Westermark P (1990) AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am J Pathol 137, 377-383.
28. Westermark GT, Sletten K & Westermark P (1989) Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 30, 605-613.
29. Westermark GT, Westermark P & Sletten K (1987) Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 57, 57-64.
30. Kelly JW & Lansbury PTJ (1994) A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid 1, 186-205.
31. Lashuel HA, Lai Z & Kelly JW (1998) Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37, 17851-17864.
32. Pras M, Prelli F, Franklin EC & Frangione B (1983) Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 80, 539-542.
33. Felding P, Fex G, Westermark P, Olofsson B-O, Pitkänen P & Benson L (1985) Prealbumin in Swedish patients with senile systemic amyloidosis and familial amyloidotic polyneuropathy. Scand J Immunol 21, 133-140.
34. Westermark P, Sletten K & Olofsson B-O (1987) Prealbumin variants in the amyloid fibrils of Swedish familial amyloidotic polyneuropathy. Clin Exp Immunol 69, 695-701.
35. Westermark P, Johansson B, Bergman C, Olofsson BO, Westermark GT & Sletten K (1990) Senile systemic amyloidosis and Swedish familial amyloidotic polyneuropathy. Similarities and dissimilarities. In Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders (Costa, PP, de Freitas, AF & Saraiva, MJM, eds), pp. 147-150. Arquivos de Medicina, Porto.
36. Bergström J, Gustavsson Å, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson B-O & Westermark P (2005) Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 206, 224-232.
37. Ancsin JB & Kisilevsky R (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274, 7172-7181.
38. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ & Pepys MB (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid component gene. Nat Med 3, 855-859.
39. McDubbin WD, Kay CM, Narindrasorasak S & Kisilevsky R (1988) Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 256, 775-783.
40. Coker AR, Purvis A, Baker D, Pepys MB & Wood SP (2000) Molecular chaperone properties of serum amyloid P component. FEBS Lett 473, 199-202.
41. Kisilevsky R & Fraser P (1996) Proteoglycans and amyloid fibrillogenesis. Ciba Found Symp 1999, 58-67.
42. Petkova AT, Leapman RD, Guo Z, Yau W-M, Mattson MP & Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265.
43. Werdelin O & Ranløv P (1966) Amyloidosis in mice produced by transplantation of spleen cells from casein-treated mice. Acta Pathol Microbiol Scand 68, 1-18.
44. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ & Skinner M (1982) Further characterization of amyloid-enhancing factor. Lab Invest 47, 139-146.
45. Ganowiak K, Hultman P, Engström U, Gustavsson Å & Westermark P (1994) Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 199, 306-312.
46. Johan K, Westermark GT, Engström U, Gustavsson Å, Hultman P & Westermark P (1998) Acceleration of AA-amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 95, 2558-2563.
47. Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A & Westermark P (2002) Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99, 6979-6984.
48. Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, Li F, Guo Z, Hosokawa M, Mori M & Higuchi K (2001) Transmission of mouse senile amyloidosis. Lab Invest 81, 493-499.
49. Xing Y, Nakamura A, Korenaga T, Guo Z, Yao J, Fu X, Matsushita T, Kogishi K, Hosokawa M, Kametani F et al. (2002) Induction of protein conformational change in mouse senile amyloidosis. J Biol Chem 277, 33164-33169.
50. Korenaga T, Fu X, Xing Y, Matsushita T, Kuramoto K, Syumiya S, Hasegawa K, Naiki H, Ueno M, Ishihara T et al. (2004) Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils. Am J Pathol 164, 1597-1606.
51. O'Nuallain B & Wetzel R (2002) Conformational abstract recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99, 1485-1490.
52. Solomon A, Weiss DT & Wall JS (2003) Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 18, 853-860.
53. Bergström J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U & Westermark P (2004) Two different types of amyloid deposits - apolipoprotein A-IV and transthyretin: a patient with systemic amyloidosis. Lab Invest 84, 981-988.
54. Lundmark K, Westermark GT, Olsén A & Westermark P (2005) Protein fibrils in nature can enhance AA amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 102, 6098-6102.
55. Linke RP, Joswig R, Murphy CL, Wang S, Zhou H, Gross U, Rocken C, Westermark P, Weiss DT & Solomon A (2005) Senile seminal veiscle amyloid is derived from semenogelin I. J Lab Clin Med 145, 187-193.